Sign In
Buy SKVI
$0.438
+0 (+0%)
At Close: Jun 23, 2026
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
05:30am, Thursday, 23'rd Jan 2025
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
06:30am, Thursday, 03'rd Oct 2024
Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / Oct
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
12:15pm, Thursday, 11'th Jul 2024
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Ph
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
09:03am, Monday, 24'th Jun 2024
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an inn
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
09:00am, Wednesday, 14'th Feb 2024
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P
